GDF15 research from bench to bedside

Samuel N Breit; David A Brown; Vicky W W Tsai

doi:10.1016/j.ccell.2024.10.002

GDF15 research from bench to bedside

Cancer Cell. 2024 Nov 11;42(11):1823-1824. doi: 10.1016/j.ccell.2024.10.002. Epub 2024 Oct 24.

Authors

Samuel N Breit¹, David A Brown², Vicky W W Tsai³

Affiliations

¹ St Vincent's Centre for Applied Medical Research, St Vincent's Hospital, Sydney, NSW 2010, Australia; The University of New South Wales, Sydney, NSW 2052, Australia. Electronic address: s.breit@unsw.edu.au.
² NSW Health Pathology-ICMPR, Westmead Hospital, Westmead, NSW 2145, Australia; Centre for Immunology and Allergy Research, The Westmead Institute for Medical Research, University of Sydney, Westmead, NSW 2145, Australia.
³ St Vincent's Centre for Applied Medical Research, St Vincent's Hospital, Sydney, NSW 2010, Australia; The University of New South Wales, Sydney, NSW 2052, Australia. Electronic address: vicky.tsai@svha.org.au.

PMID: 39454578
DOI: 10.1016/j.ccell.2024.10.002

Abstract

Pre-clinical data suggest that increased circulating growth differentiation factor 15 (GDF15) is a cause of both anorexia/cachexia syndromes and hyperemesis gravidarum in pregnancy, serious conditions with no highly effective treatment. A phase 2 study of a therapeutic GDF15 monoclonal antibody in the New England Journal of Medicine suggests that effective treatment of anorexia/cachexia in cancer may be approaching.

MeSH terms

Animals
Anorexia
Antibodies, Monoclonal / therapeutic use
Female
Growth Differentiation Factor 15* / metabolism
Humans
Hyperemesis Gravidarum / therapy
Neoplasms
Pregnancy

Substances

Growth Differentiation Factor 15
GDF15 protein, human
Antibodies, Monoclonal